|
IL166546A0
(en)
|
2002-08-05 |
2006-01-15 |
Atugen Ag |
Further novel forms of interfering ran molecules
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
US7750144B2
(en)
*
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
CA2528012C
(en)
|
2003-06-02 |
2015-11-24 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of rna silencing
|
|
US8309704B2
(en)
*
|
2003-06-02 |
2012-11-13 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNAi
|
|
US8680063B2
(en)
*
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
EP1670518B1
(en)
*
|
2003-09-12 |
2014-05-21 |
University of Massachusetts |
Rna interference for the treatment of gain-of-function disorders
|
|
US20060134787A1
(en)
*
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
WO2005089287A2
(en)
|
2004-03-15 |
2005-09-29 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
EP2239328A3
(en)
*
|
2005-08-18 |
2011-01-05 |
Alnylam Pharmaceuticals Inc. |
Methods and compositions for treating neurological disease
|
|
AU2007283022B2
(en)
|
2006-08-08 |
2011-07-28 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Structure and use of 5' phosphate oligonucleotides
|
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
|
WO2009141146A1
(en)
|
2008-05-21 |
2009-11-26 |
Gunther Hartmann |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
TWI455944B
(zh)
*
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
EP2323695B1
(en)
|
2008-08-19 |
2018-12-05 |
Nektar Therapeutics |
Complexes of small-interfering nucleic acids
|
|
US8225729B2
(en)
*
|
2008-12-16 |
2012-07-24 |
Kimberly-Clark Worldwide, Inc. |
Three-dimensional wiping substrate and method therefor
|
|
US11408003B2
(en)
|
2008-12-18 |
2022-08-09 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
WO2010080129A2
(en)
*
|
2008-12-18 |
2010-07-15 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
US20120022142A1
(en)
*
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
CA2757613C
(en)
*
|
2009-04-03 |
2023-10-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna
|
|
EP2756845B1
(en)
*
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
|
US20120114710A1
(en)
*
|
2009-05-18 |
2012-05-10 |
Lynn Kirkpatrick |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
|
WO2010141933A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Specific inhibition of gene expression by nucleic acid containing a dicer substrate
|
|
EP2440666B1
(en)
|
2009-06-10 |
2017-03-01 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (vigs) for functional analysis of genes in cotton
|
|
CA2767127A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
WO2011072082A2
(en)
|
2009-12-09 |
2011-06-16 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
|
WO2011072292A2
(en)
*
|
2009-12-11 |
2011-06-16 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of rna and rna derivatives
|
|
JP5257796B2
(ja)
*
|
2009-12-28 |
2013-08-07 |
株式会社村田製作所 |
固体電解コンデンサ素子及びその製造方法
|
|
PT3587579T
(pt)
|
2010-07-06 |
2021-05-24 |
Dicerna Pharmaceuticals Inc |
Métodos e composições para a inibição específica de beta-catenina por rna de filamento duplo
|
|
WO2012006241A2
(en)
|
2010-07-06 |
2012-01-12 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2622064B1
(en)
|
2010-10-01 |
2019-05-29 |
Modernatx, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
WO2012056440A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
|
|
KR101937498B1
(ko)
|
2011-03-03 |
2019-04-10 |
쿠아크 파마수티칼스 인코퍼레이티드 |
폐 질환 및 손상을 치료하기 위한 조성물 및 방법
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
|
SG195304A1
(en)
|
2011-06-10 |
2013-12-30 |
Temasek Life Sciences Lab Ltd |
Genetic manipulation and expression systems for pucciniomycotina and ustilaginomycotina subphyla
|
|
WO2012173994A2
(en)
*
|
2011-06-15 |
2012-12-20 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of nucleic acid payloads
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3492109B1
(en)
|
2011-10-03 |
2020-03-04 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
CN103987847B
(zh)
|
2011-10-18 |
2017-06-16 |
迪克纳制药公司 |
胺阳离子脂质及其用途
|
|
KR20150021489A
(ko)
|
2011-11-18 |
2015-03-02 |
알닐람 파마슈티칼스 인코포레이티드 |
변형된 ＲＮＡｉ 제제
|
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
SG11201405157PA
(en)
|
2012-02-24 |
2014-10-30 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
WO2013158032A1
(en)
|
2012-04-19 |
2013-10-24 |
Temasek Life Sciences Laboratory Limited |
Methods for increasing cotton fiber length
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
KR20150095763A
(ko)
*
|
2012-12-14 |
2015-08-21 |
다이서나 파마수이티컬, 인크. |
이중쇄 rna에 의한 ckap5의 특이적 저해를 위한 방법 및 조성물
|
|
AU2014236250B2
(en)
|
2013-03-14 |
2019-01-03 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
PL3444350T3
(pl)
|
2013-07-03 |
2022-03-21 |
Dicerna Pharmaceuticals, Inc. |
Sposoby i kompozycje do specyficznego hamowania alfa-1 antytrypsyny przez dwuniciowy rna
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
SG11201602503TA
(en)
|
2013-10-03 |
2016-04-28 |
Moderna Therapeutics Inc |
Polynucleotides encoding low density lipoprotein receptor
|
|
AU2014360314B2
(en)
|
2013-12-06 |
2018-04-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
EP3892727A1
(en)
|
2013-12-27 |
2021-10-13 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
|
|
WO2016057932A1
(en)
|
2014-10-10 |
2016-04-14 |
Dicerna Pharmaceuticals, Inc. |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
|
CN107002062A
(zh)
|
2014-10-22 |
2017-08-01 |
淡马锡生命科学研究院有限公司 |
来自依兰fruticosa 变种(Cananga odorata var. fruticosa)的萜烯合酶
|
|
WO2016100401A1
(en)
|
2014-12-15 |
2016-06-23 |
Dicerna Pharmaceuticals, Inc. |
Ligand-modified double-stranded nucleic acids
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
WO2016183009A2
(en)
|
2015-05-08 |
2016-11-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
|
|
CA2991052A1
(en)
*
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
PL3506909T3
(pl)
|
2016-09-02 |
2022-09-12 |
Dicerna Pharmaceuticals, Inc. |
Analogi 4’- fosforanu i zawierające je oligonukleotydy
|
|
EP3696270A4
(en)
*
|
2017-10-11 |
2021-07-07 |
Nitto Denko Corporation |
REGULATION OF THE EXPRESSION OF NUCLEIC ACID MOLECULES
|
|
CN118440940A
(zh)
|
2017-10-13 |
2024-08-06 |
诺和诺德保健股份有限公司 |
用于抑制ldha表达的方法和组合物
|
|
CA3078960A1
(en)
|
2017-10-20 |
2019-04-25 |
Dicerna Pharmaceuticals, Inc. |
Methods for treating hepatitis b infection
|
|
AU2019205904A1
(en)
|
2018-01-05 |
2020-06-18 |
Dicerna Pharmaceuticals, Inc. |
Reducing beta-catenin and IDO expression to potentiate immunotherapy
|
|
WO2019143621A1
(en)
|
2018-01-16 |
2019-07-25 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting aldh2 expression
|
|
WO2020011902A1
(en)
|
2018-07-13 |
2020-01-16 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating rtel1 expression
|
|
EP4043015A1
(en)
|
2018-09-04 |
2022-08-17 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Delta-tocotrienol for treating cancer
|
|
WO2020142693A1
(en)
*
|
2019-01-04 |
2020-07-09 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts
|
|
CN113692444A
(zh)
|
2019-02-12 |
2021-11-23 |
迪克纳制药公司 |
用于抑制cyp27a1的表达的方法和组合物
|
|
WO2020205473A1
(en)
|
2019-03-29 |
2020-10-08 |
Decerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
CA3135402A1
(en)
|
2019-04-04 |
2020-10-08 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression in the central nervous system
|
|
WO2020226960A1
(en)
|
2019-05-03 |
2020-11-12 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
MX2022002533A
(es)
|
2019-08-30 |
2022-06-02 |
Dicerna Pharmaceuticals Inc |
Ácidos nucleicos modificados con ligandos 2', síntesis de estos y compuestos intermedios de estos.
|
|
CA3153026A1
(en)
|
2019-10-02 |
2021-04-08 |
Weimin Wang |
Chemical modifications of small interfering rna with minimal fluorine content
|
|
MX2022007909A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
|
|
EP4081639A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
MX2022011550A
(es)
|
2020-03-18 |
2023-01-04 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión de angptl3.
|
|
CA3187220A1
(en)
|
2020-08-04 |
2022-02-10 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
|
US20240084309A1
(en)
|
2020-08-04 |
2024-03-14 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting plp1 expression
|
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
|
IL300338A
(en)
|
2020-08-05 |
2023-04-01 |
Dicerna Pharmaceuticals Inc |
Compounds and methods for inhibiting the expression of LPA
|
|
KR20230043877A
(ko)
|
2020-08-05 |
2023-03-31 |
에프. 호프만-라 로슈 아게 |
B형 간염 환자의 올리고뉴클레오티드 치료
|
|
BR112023017367A2
(pt)
|
2021-04-12 |
2023-12-12 |
Boehringer Ingelheim Int |
Composições e métodos para inibição de ceto-hexoquinase (khk)
|
|
AR125351A1
(es)
|
2021-04-14 |
2023-07-12 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión de pnpla3
|
|
EP4326872A2
(en)
|
2021-04-19 |
2024-02-28 |
Novo Nordisk A/S |
Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
|
|
TWI831225B
(zh)
|
2021-05-28 |
2024-02-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於抑制粒線體胺肟還原組分１（ｍａｒｃ１）表現之組合物及方法
|
|
EP4392556A1
(en)
|
2021-08-25 |
2024-07-03 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting ?lpha-1 antitrypsin expression
|
|
CN118284695A
(zh)
|
2021-11-11 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的药物组合
|
|
CN118355120A
(zh)
|
2021-12-01 |
2024-07-16 |
迪克纳制药公司 |
用于调节apoc3表达的组合物和方法
|
|
AR129073A1
(es)
|
2022-04-15 |
2024-07-10 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para modular la actividad de scap
|
|
TW202400792A
(zh)
|
2022-05-12 |
2024-01-01 |
美商戴瑟納製藥股份有限公司 |
用於抑制ｍａｐｔ表現之組合物及方法
|
|
WO2023220351A1
(en)
|
2022-05-13 |
2023-11-16 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting snca expression
|
|
TWI868755B
(zh)
|
2022-06-24 |
2025-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
|
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
AR133386A1
(es)
|
2023-07-28 |
2025-09-24 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para la expresión del receptor del ligando de muerte programada (pd-l1)
|
|
WO2025054459A1
(en)
|
2023-09-08 |
2025-03-13 |
Dicerna Pharmaceuticals, Inc. |
Rnai oligonucleotide conjugates
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|